Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 16:50
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
Twitch streamer Kai Cenat's 'giveaway' sparks chaos in Manhattan
Ninja: Which gaming headset does pro gamer use? Here's what you need to know
Tristan Tate: Andrew Tate's brother heaps praises on MrBeast for 'awesome' physical transformation, 'setting a good example'
Top Emitter China Needs $38 Trillion to Hit Climate Goals Early
'Scream VI' writers and Jasmin Savoy Brown reveal the most crucial horror movie survival rules
How tall is Josh Richards? Influencer once justified Andrew Tate's sexist remarks and hateful speech
The Yeedi Mop Station Pro looks futuristic as hell — but is it worth the investment?
When Does The First Descendant Beta Start?